These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29228829)

  • 1. Vanadium pentoxide increased PTEN and decreased SHP1 expression in NK-92MI cells, affecting PI3K-AKT-mTOR and Ras-MAPK pathways.
    Gallardo-Vera F; Tapia-Rodriguez M; Diaz D; Fortoul van der Goes T; Montaño LF; Rendón-Huerta EP
    J Immunotoxicol; 2018 Dec; 15(1):1-11. PubMed ID: 29228829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vanadium pentoxide prevents NK-92MI cell proliferation and IFNγ secretion through sustained JAK3 phosphorylation.
    Gallardo-Vera F; Diaz D; Tapia-Rodriguez M; Fortoul van der Goes T; Masso F; Rendon-Huerta E; Montaño LF
    J Immunotoxicol; 2016; 13(1):27-37. PubMed ID: 25565016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.
    Lim HJ; Wang X; Crowe P; Goldstein D; Yang JL
    Anticancer Res; 2016 Nov; 36(11):5765-5771. PubMed ID: 27793898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nickel-doped vanadium pentoxide (Ni@V
    Nivetha S; Srivalli T; Sathya PM; Mohan H; Karthi N; Muralidharan K; Ramalingam V
    Colloids Surf B Biointerfaces; 2024 Feb; 234():113763. PubMed ID: 38262106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.
    Chappell WH; Steelman LS; Long JM; Kempf RC; Abrams SL; Franklin RA; Bäsecke J; Stivala F; Donia M; Fagone P; Malaponte G; Mazzarino MC; Nicoletti F; Libra M; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Laidler P; Milella M; Tafuri A; Bonati A; Evangelisti C; Cocco L; Martelli AM; McCubrey JA
    Oncotarget; 2011 Mar; 2(3):135-64. PubMed ID: 21411864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
    Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway.
    Guo Y; Chang H; Li J; Xu XY; Shen L; Yu ZB; Liu WC
    Apoptosis; 2015 Aug; 20(8):1109-21. PubMed ID: 26002438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
    Wang T; Seah S; Loh X; Chan CW; Hartman M; Goh BC; Lee SC
    Oncotarget; 2016 Jan; 7(3):2532-44. PubMed ID: 26565813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid attenuates diabetic mesangial cell injury through the up-regulation of autophagy via miRNA-21/PTEN/Akt/mTOR suppression.
    Lu X; Fan Q; Xu L; Li L; Yue Y; Xu Y; Su Y; Zhang D; Wang L
    PLoS One; 2015; 10(2):e0117400. PubMed ID: 25689721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.
    Su YC; Li SC; Hsu CK; Yu CC; Lin TJ; Lee CY; Liao HF
    Bone Marrow Transplant; 2012 Jan; 47(1):73-81. PubMed ID: 21358682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
    Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
    J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (‑)‑Epigallocatechin‑3‑gallate induces apoptosis in human pancreatic cancer cells via PTEN.
    Liu S; Xu ZL; Sun L; Liu Y; Li CC; Li HM; Zhang W; Li CJ; Qin W
    Mol Med Rep; 2016 Jul; 14(1):599-605. PubMed ID: 27176210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer.
    Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS
    Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis induced by the methanol extract of Salvia miltiorrhiza Bunge in non-small cell lung cancer through PTEN-mediated inhibition of PI3K/Akt pathway.
    Ye YT; Zhong W; Sun P; Wang D; Wang C; Hu LM; Qian JQ
    J Ethnopharmacol; 2017 Mar; 200():107-116. PubMed ID: 28088493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the PI3K-Akt-mTOR signaling pathway in T lymphocytes in patients with active tuberculosis.
    Zhang X; Huang T; Wu Y; Peng W; Xie H; Pan M; Zhou H; Cai B; Wu Y
    Int J Infect Dis; 2017 Jun; 59():110-117. PubMed ID: 28416440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.